Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$27,000.00

Investigating the role of FOXM1 in breast cancer progression

EF 2024-25

Résumé
Investigating the role of FOXM1 in breast cancer progressionBreast cancer is a prevalent disease among Canadian women, including the aggressive and highly proliferative Luminal B subtype found in 15-20% of patients. The current standard of care for hormone receptor-positive breast cancers are endocrine therapies, however some patients experience therapy resistance or declining response. FOXM1, a master regulator of cell cycle progression, plays a crucial role in breast tumor growth and metastasis and its expression is elevated in most human cancers. Indirect genetic and drug-induced loss of FOXM1 prevents tumour growth in Luminal B breast cancers, which has been demonstrated in cell and mouse models. Additionally, there are initial findings indicating that levels of FOXM1 are elevated in cell cycle inhibitor-resistant cells. Our study will evaluate the effects of FOXM1 loss on cancer cell growth and investigate the role of FOXM1 in cell cycle inhibitor-resistant cells. Short and long-term loss of FOXM1 in breast tissue will be evaluated in mouse models to investigate if tumour initiation, progression, and metastasis are delayed. We will evaluate different expressed pathways to identify genes of interest involved downstream of FOXM1 in breast cancer progression. Furthermore, we aim to develop a direct inhibitor of FOXM1 and study its effect on tumor progression in mouse models. These compounds can be tested in addition to the standard of care in patient-derived models to determine if cell cycle inhibitor efficacy can be improved. Our research will elucidate important insights into the direct role FOXM1 plays in cancer cell growth and metastasis, as well as suggest alternative therapies for patients with this type of breast cancer struggling with inhibitor resistance.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
530190
Name
Bettenson Lauren M
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the role of FOXM1 in breast cancer progression
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Cell Cycle; Endocrine Therapy; Foxm1; Genetically Engineered Mouse Model; Luminal B; Proliferation; Protac; Resistance
Abstract
Investigating the role of FOXM1 in breast cancer progressionBreast cancer is a prevalent disease among Canadian women, including the aggressive and highly proliferative Luminal B subtype found in 15-20% of patients. The current standard of care for hormone receptor-positive breast cancers are endocrine therapies, however some patients experience therapy resistance or declining response. FOXM1, a master regulator of cell cycle progression, plays a crucial role in breast tumor growth and metastasis and its expression is elevated in most human cancers. Indirect genetic and drug-induced loss of FOXM1 prevents tumour growth in Luminal B breast cancers, which has been demonstrated in cell and mouse models. Additionally, there are initial findings indicating that levels of FOXM1 are elevated in cell cycle inhibitor-resistant cells. Our study will evaluate the effects of FOXM1 loss on cancer cell growth and investigate the role of FOXM1 in cell cycle inhibitor-resistant cells. Short and long-term loss of FOXM1 in breast tissue will be evaluated in mouse models to investigate if tumour initiation, progression, and metastasis are delayed. We will evaluate different expressed pathways to identify genes of interest involved downstream of FOXM1 in breast cancer progression. Furthermore, we aim to develop a direct inhibitor of FOXM1 and study its effect on tumor progression in mouse models. These compounds can be tested in addition to the standard of care in patient-derived models to determine if cell cycle inhibitor efficacy can be improved. Our research will elucidate important insights into the direct role FOXM1 plays in cancer cell growth and metastasis, as well as suggest alternative therapies for patients with this type of breast cancer struggling with inhibitor resistance.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bettenson, Lauren M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~